<DOC>
	<DOCNO>NCT01749072</DOCNO>
	<brief_summary>In National Comprehensive Cancer Network ( NCCN ) guideline NSCLC , epidermal growth factor receptor-tyrosine kinase inhibitor ( EGFR-TKI ) recommend third-line treatment EGFR gene mutation negative NSCLC patient fail first-line platinum doublet chemotherapy [ i.e . paclitaxel-carboplatin ( PC ) gemcitabine-cisplatin ( GP ) ] second-line chemotherapy docetaxel pemetrexed . But know , patient EGFR gene mutation , EGFR-TKI treatment effective . The overall survival short objective response rate low . As EGFR gene wild type patient good performance status , besides EGFR-TKI treatment , first generation cytotoxic drug i.e . vinorelbine ifosfamide maybe alternative treatment . So purpose clinical trial compare effectiveness safety vinorelbine-ifosfamide gefitinib advance metastatic EGFR gene mutation negative NSCLC patient .</brief_summary>
	<brief_title>Vinorelbine-ifosfamide Versus Gefitinib EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients</brief_title>
	<detailed_description>Ifosfamide first generation cytotoxic drug treat NSCLC . Phase Ⅱ study demonstrate single-agent ifosfamide administrate various schedule produce response rate 15-29 % , medium survival time 5-7 month . Ifosfamide also use various combination regimens treat NSCLC , include platinum base non-platinum regimen . But refractory NSCLC patient platinum third generation cytotoxic drug use . So study , ifosfamide combine vinorelbine . In previous study , Masters report objective response rate 40 % median survival duration 50 week , 1-year survival rate 48 % vinorelbine-ifosfamide regimen [ Vinorelbine 15 mg/m2 day 1-3 , ifosfamide 2.0g/m2 day 1-3 granulocyte-colony stimulating factor ( G-CSF ) support ] . The dose limiting toxicity ( DLT ) regimen myelosuppression . In experience , regimen vinorelbine 25mg/m2 d1 , d8 ifosfamide 1.25g/m2 d1-d3 Mesna uroprotection safe Chinese population objective response rate 7 % ( data publish ) . Gefitinib first small molecule inhibitor direct activity towards EGFR show appreciable response rate phase Ⅱ trial patient previously treat advanced NSCLC . In posterior analysis Iressa Dose Evaluation Advanced Lung Cancer ( IDEAL ) IRESSA Survival Evaluation Lung Cancer ( ISEL ) trial , response rate gefitinib range 2.6 % 10 % wild-type EGFR gene NSCLC patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>age range:1870 year old life expectancy 12 week histologically cytologically confirm inoperable NSCLC ( stage ⅢB/Ⅳ ) ineligible curative radiotherapy prior radiotherapy target lesion Eastern Cooperative Oncology Group ( ECOG ) performance score 02 ; prior treatment include firstline platinum doublet chemotherapy i.e . PC GP secondline chemotherapy docetaxel pemetrexed ; No EGFR gene mutation detect ScorpionsARMS ; least one bidimensionally measurable radiographically assessable lesion ; adequate bone marrow reserve ; adequate hepatic renal function ; prior treatment include follow drug : gefitinib , vinorelbine ifosfamide ; additional malignancy ; uncontrolled systemic disease ; evidence clinically active interstitial lung disease ; newly diagnose central nervous system ( CNS ) metastasis treat radiotherapy surgery ; pregnancy breast feeding phase ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>gefitinib</keyword>
	<keyword>vinorelbine</keyword>
	<keyword>ifosfamide</keyword>
</DOC>